Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
NCT03927222 · Mustafa Khasraw, MBChB, MD, FRCP, FRACP · PHASE2 · terminated · last registry update 2024-04-08 · Glioblastoma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Resource shortage” | Open Targets' class: logistics resources | Registry record, Mustafa Khasraw, MBChB, MD, FRCP, FRACP |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF2RA in glioblastoma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-14Results posted on the registry: University of Florida, pp65-shLAMP DC with GM-CSF + unpulsed PBMC and saline (NCT02465268)
- 2024-08-28Results posted on the registry: David Peereboom, Pembrolizumab + SurVaxM (NCT04013672)
- 2023-12-06Results posted on the registry: Stemline Therapeutics, Inc., SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose) + Bevacizumab (NCT02078648)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision